\- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.
Study Type
OBSERVATIONAL
Enrollment
50
The patients will be treated with Avastin combined neoadjuvant chemotherapy
Xijing Hospital ， Fourth Military Medical University
Xi'an, Shaanxi, China
RECRUITINGObjective Response Rate
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
Time frame: From enrollment to disease progression
overall response
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
Time frame: From enrollment to disease progression
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.